



Date of report 16 May 2019

Reported case interaction between  
**Darunavir** and **Tejocote root**  
(**Crataegus mexicana** or  
**Crataegus pubescens**)

**Drugs suspected to be involved in the DDI**

Victim

**Darunavir**

Daily Dose

800 (mg)

Dose adjustment performed

No

Administration Route

Oral

Start date

May 17, 2016

End date

Ongoing

Perpetrator

**Tejocote root**  
(**Crataegus mexicana**  
or **Crataegus**  
**pubescens**)

Daily Dose

Unknown

Dose adjustment performed

No

Administration Route

Oral

Start date  
Unknown

End date  
Ongoing

## Complete list of drugs taken by the patient

Antiretroviral treatment  
Darunavir/Cobicistat  
Dolutegravir

Complete list of all comedications taken by the patient, included that involved in the DDI

Tejocote root (*Crataegus mexicana* or *Crataegus pubescens*),  
Diclofenac

## Clinical case description

Gender  
Male

Age  
49

eGFR (mL/min)  
>60

Liver function impairment  
No

### Description

Patient taking Tejocote root (*Crataegus mexicana* or *Crataegus pubescens*) to loose weight. *Crataegus mexicana* can inhibit UGT, increasing concentrations of drugs metabolized through this pathway. It may also induce CYP3A4, potentially decreasing concentrations of drugs metabolized through this pathway. Furthermore, it has alkaloids with similar structure to digoxin, so it could interfere in its pharmacodynamic action (Source: Memorial Sloan Kettering Cancer Center database) The patient had detectable viral load, but without selecting resistance

mutations. This could be due to irregular adherence and/or to the high genetic barrier of both drugs in the regimen.

## Clinical Outcome

**Loss of efficacy**

## Drug Interaction Probability Scale (DIPS)

Score

**2 - Possible**

## Editorial Comment

*Cratageus mexicana* can inhibit UGT, increasing concentrations of drugs metabolized through this pathway. It may also induce CYP3A4, potentially decreasing concentrations of drugs metabolized through this pathway. Furthermore, it has alkaloids with similar structure to digoxin, so it could interfere in its pharmacodynamic action (Source: Memorial Sloan Kettering Cancer Center database)

## University of Liverpool Recommendation

N/A